The influenza A (H1N1) 2009 vaccine produced by GlaxoSmithKline has been approved by Canada Health. Here is some information on the vaccine to supplement what I’ve provided about the US counterparts. The Canadian vaccine, called Arepanrix H1N1, is supplied in two parts. One contains inactivated H1N1 influenza virus, and the second consists of AS03 adjuvant …
The World Health Organization recently convened a meeting of 100 clinicians, scientists, and public health professionals to discuss the clinical features of pandemic influenza. They concluded that the vast majority of infections with the 2009 H1N1 influenza virus were uncomplicated and are followed by full recovery within 7 days. However, some patients, including children, develop …
There have been many interesting responses to my recent post, “Are you receiving the influenza 2009 H1N1 vaccine?” Some individuals have already been immunized or plan to do so shortly. Others are concerned about the safety and efficacy of the monovalent preparations. As pointed out recently in a Nature editorial, “Mass-vaccination campaigns…must take public concerns …
Influenza A (H1N1) 2009 vaccine: efficacy and safety Read More »
1. Some parasitic wasps lay eggs in caterpillars, where they mature into adult wasps. The wasp eggs contain a virus, encoded in the wasp genome, which prevents the caterpillar from rejecting the eggs. 2. There are a million virus particles per milliliter of seawater €“ for a global total of 1030 virions! Lined up end …
Hosts: Vincent Racaniello and Lynn Enquist On episode 54 of the podcast “This Week in Virology”, Vincent speaks with Lynn Enquist about his career in virology, moving from academia to industry and back. Along the way Prof. Enquist did pioneering research on bacteriophage, participated in the birth of recombinant DNA technology, and studied herpesviruses. [powerpress …
TWiV 54: Professor Lynn Enquist, virology luminary Read More »
Because of concerns about the safety and efficacy of the new vaccine against 2009 H1N1 influenza (swine flu) Marc Pelletier, PhD from Futures in Biotech and I teamed up to record a public service announcement to encourage vaccination. This announcement addresses safety and side effects, which are expected to be similar to those from any …
